Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-033: Sacituzumab tirumotecan plus pembrolizumab maintenance in pMMR endometrial cancer
jRCT2011250020Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan and pembrolizumab in endometrial cancer (EC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Sep 2025; status: recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2011250020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250020.